Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30628220 | 0.76 | KDM4E (0.63) | ALDH1A1TSHRLMNA | |
| SCHEMBL17420569 | 0.76 | KDM4E (0.63) | ALDH1A1TSHRLMNA | |
| SCHEMBL17420730 | 0.74 | KMO (0.58) | ALOX15HSD17B10ALDH1A1TSHRNPSR1 | |
| SCHEMBL30628288 | 0.74 | KMO (0.58) | ALOX15HSD17B10ALDH1A1TSHRNPSR1 | |
| SCHEMBL5912618 | 0.73 | ALDH1A1 (0.43) | ALOX15HSD17B10ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL8927341 | 0.73 | SMN1; SMN2 (0.43) | ALDH1A1TSHRSMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL11292175 | 0.73 | MEN1 (0.43) | ALDH1A1TSHRSMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL31256902 | 0.72 | CES2 (0.49) | TSHRSMN1; SMN2NPSR1LMNA | |
| SCHEMBL22285693 | 0.72 | CES2 (0.49) | TSHRSMN1; SMN2NPSR1LMNA | |
| SCHEMBL17420415 | 0.71 | NCF1 (0.52) | ALDH1A1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111170991-B | Antiproliferative compounds and methods of synthesis thereof | 细胞基因公司 | 2023-10-31 | — | — | CN | disclosed |
| EP-3594211-B1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20220387413-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2022-12-08 | — | — | US | disclosed |
| US-11241423-B2 | Antiproliferative compounds and methods of use thereof | CELGENE CORPORATION (US) | 2022-02-08 | — | — | US | disclosed |
| US-20200163948-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2020-05-28 | — | — | US | disclosed |
| CN-111170991-A | Antiproliferative compounds and methods of synthesis thereof | 细胞基因公司 | 2020-05-19 | — | — | CN | disclosed |
| CN-106660991-B | Antiproliferative compounds and methods of use thereof | 细胞基因公司 | 2020-03-13 | — | — | CN | disclosed |
| EP-3166937-B1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2019-09-04 | — | — | EP | disclosed |
| US-20180221361-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2018-08-09 | — | — | US | disclosed |
| US-9968596-B2 | Antiproliferative compounds and methods of use thereof | CELGENE CORPORATION (US) | 2018-05-15 | — | — | US | disclosed |
| US-20180021325-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2018-01-25 | — | — | US | disclosed |
| US-9808451-B2 | Antiproliferative compounds and methods of use thereof | CELGENE CORPORATION (US) | 2017-11-07 | — | — | US | disclosed |
| EP-3166937-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | Celgene Corporation (US) | 2017-05-17 | — | — | EP | disclosed |
| US-20170007590-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORP (US) | 2017-01-12 | — | — | US | disclosed |
| US-9499514-B2 | Antiproliferative compounds and methods of use thereof | CELGENE CORPORATION (US) | 2016-11-22 | — | — | US | disclosed |
| US-20160009683-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORPORATION | 2016-01-14 | — | — | US | disclosed |
| WO-2016007848-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORPORATION (US) | 2016-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387413-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | MCL1, MKI67, BAX | KCNA5 4753/4885ALOX15 424/4885HSD17B10 3440/4885 |
| US-20170007590-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | MCL1, MKI67, BAX | KCNA5 4753/4885ALOX15 424/4885HSD17B10 3440/4885 |
| US-11241423-B2 | Antiproliferative compounds and methods of use thereof | MCL1, MKI67, BAX | KCNA5 4753/4885ALOX15 424/4885HSD17B10 3440/4885 |
| US-20200163948-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | MCL1, MKI67, BAX | KCNA5 4753/4885ALOX15 424/4885HSD17B10 3440/4885 |
| US-20160009683-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | MCL1, MKI67, BAX | KCNA5 4753/4885ALOX15 424/4885HSD17B10 3440/4885 |
| US-20180021325-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | MCL1, MKI67, BAX | KCNA5 4753/4885ALOX15 424/4885HSD17B10 3440/4885 |
| US-20180221361-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | MCL1, MKI67, BAX | KCNA5 4753/4885ALOX15 424/4885HSD17B10 3440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.